why choose us

First received: August 01, 2023

Clinical Trial: Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cancer

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Sol

Brief Summary: This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment.Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens.Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs.Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and evaluate incidence and…

Read more